Bard to buy back shares:
This article was originally published in Clinica
CR Bard's board of directors has authorised the buyback of up to 5 million shares. This follows a 10 million share buyback authorised in July 1998 that is almost complete. The company has also announced a constant currency revenue growth forecast of 7-8% for 2003, with earnings per share excluding this year's non-recurring items expected to rise by 12% over 2002. Bard's share price closed at $56.80 following the announcements, down slightly on recent trading.
You may also be interested in...
Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.
Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.